Business
OmniAb to Report Fourth Quarter 2022 Financial Results on March 30
EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2022 after the
About this update from Omniab, Inc.
[{"type":"text","content":" EMERYVILLE, Calif.--(BUSINESS WIRE)--\nOmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, March 30, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.\n\nConference Call and Webcast Information\n\n\n\nWhat:\n\n\n\n \n\n\n\nOmniAb conference call to discuss financial results and business updates\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nDate:\n\n\n\n \n\n\n\nThursday, March 30, 2023\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nTime:\n\n\n\n \n\n\n\n4:30 p.m. Eastern time (1:30 p.m. Pacific time)\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nConference Call:\n\n\n\n \n\n\n\nU.S. (888) 886-7786\n\n\n\n\n\n \n\n\n\n \n\n\n\nInternational +1 (416) 764-8658\n\n\n\n\n\n \n\n\n\n \n\n\n\nConference ID is 43857264\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nWebcast:\n\n\n\n \n\n\n\nLive and replay webcast of the call with slides will be available here.\n\n\n\n\nAbout OmniAb®\n\nOmniAb, Inc.’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic® (transgenic rat) and OmniClic® (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur™ features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities in emerging target c...